The increased insulin sensitivity in growth hormone‐deficient adults is reduced by growth hormone replacement therapy
Authors:
- M RiedlMRM Riedl
- B LudvikBLB Ludvik
- G PaciniGPG Pacini
- M ClodiMCM Clodi
- H KotzmannHKH Kotzmann
- O WagnerOWO Wagner
- Kautzky‐ WillerKautzky‐ Willer
- R PragerRPR Prager
- A LugerALA Luger
- 1 September 2000
- journal article
- clinical trial
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 30 (9) , 771-778
Abstract
Background: Growth hormone deficiency is associated with increased morbidity and mortality from cardiovascular diseases, which might be related to changes in glucose and lipid metabolism.Design: To assess the influence of long‐term growth hormone replacement therapy (GHRT) on glucose metabolism we examined eight growth hormone‐deficient (GHD) adults (seven female/one male; age, 46 ± 3 years; body mass index, 31 ± 2 kg m−2) over a period of 18 months in comparison to an adequate control group consisting of eight obese subjects matched for age, sex, and body mass index. We performed frequently sampled intravenous glucose tolerance tests (FSIGT) with minimal model analysis before the study, and after 12 and 18 months.Results: Following GHRT, insulin‐like growth factor‐1 (IGF‐1) increased significantly from a basal level of 75.9 ± 18.9 to 200.8 ± 31.0 μg L−1 after 12 months of therapy and remained stable, thereafter. GHRT did not affect fasting blood glucose, basal insulin, cholesterol, blood pressure and body weight. However, at 12 months, HbA1c (6.0 ± 0.1 vs. 5.6 ± 0.1% at basal, P < 0.05) and triglyceride (2.3 ± 0.4 vs. 1.4 ± 0.3 mmol L−1) significantly increased but returned to pretreatment values at 18 months. Insulin sensitivity was higher in GHD (8.2 ± 3.1) compared to controls (3.6 ± 0.53 × 10−4 min−1/(μU mL−1), P = 0.06) and decreased significantly after 18 months of GHRT to 5.1 ± 2.6, P < 0.05. Basal insulin secretion was similar to that in the control group and increased significantly after 12 and 18 months, total insulin secretion only after 12 months. SG (glucose effectiveness)was lower in GHD patients (0.0095 ± 0.001 min−1) compared to controls (0.020 ± 0.003 min−1, P < 0.05) and increased significantly after 12 and 18 months of GHRT (0.016 ± 0.002, and 0.015 ± 0.001 min−1, P < 0.05), respectively. Hepatic insulin extraction rate was similar in both groups and remained unchanged following GHRT.Conclusion: We conclude that long‐term GHRT induces a significant decrease of the increased insulin sensitivity in GHD patients to levels observed in body mass index‐matched control subjects. This is accompanied by an increase in basal and total insulin secretion as well as in glucose effectiveness as a possible compensatory mechanism.Keywords
This publication has 41 references indexed in Scilit:
- Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiencyClinical Endocrinology, 1998
- Increased cerebrovascular mortality in patients with hypopituitarismClinical Endocrinology, 1997
- The effect of hypopituitarism on life expectancyThe Journal of Clinical Endocrinology & Metabolism, 1996
- Cardiac structural and functional abnormalities in adult patients with growth hormone deficiencyThe Journal of Clinical Endocrinology & Metabolism, 1993
- Treatment of adults with growth hormone (GH) deficiency with recombinant human GHThe Journal of Clinical Endocrinology & Metabolism, 1993
- Aortic distensibility in growth hormone deficient adultsThe Lancet, 1993
- Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiencyClinical Endocrinology, 1993
- Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adultsThe Lancet, 1992
- Erhöhte Prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzlichen Wachstumshormonsubstitution?Journal of Molecular Medicine, 1991
- Premature mortality due to cardiovascular disease in hypopituitarismThe Lancet, 1990